相关实验视频

Updated: May 31, 2025

Vessel-sparing Excision and Primary Anastomosis

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

老年伴并发性患有良性前列腺增生症的前列腺动脉栓塞:临床失败的安全性,有效性和预测因素

Federico Zorzi¹, Giulio Rossin¹, Michelangelo Digregorio²

¹Urology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34126 Trieste, Italy.

Journal of personalized medicine

|January 24, 2025

概括

前列腺动脉栓塞 (PAE) 有效地治疗老年多病症男性的良性前列腺激增症 (BPH). 较高的并发症指数和空虚后的残留尿液预测了较差的结果,指导患者选择这种安全的手术.

科学领域:

干预性泌尿器科干预性泌尿器科
老年医学老年医学
血管干预血管干预

背景情况:

良性前列腺增生症 (BPH) 显著影响老年,多病患者.
前列腺动脉栓塞 (PAE) 是BPH的新兴治疗选择.
在复杂的患者群体中,安全性和有效性需要彻底评估.

研究的目的:

评估PAE在老年多病性BPH患者的安全性和有效性.
为了确定PAE后中期临床失败的预测因素.
为了将技术和临床因素与治疗结果相关联.

主要方法:

连续175名PAE患者的回顾性分析.
使用Clavien-Dindo分类对安全性的评估.
术前和术后的国际前列腺症状评分 (IPSS),生活质量 (QoL),前列腺体积 (PV),前列腺特异性抗原 (PSA),最大尿流率 (Qmax) 和空虚后残留尿液 (PVR) 的比较.
回归模型用于识别临床失败预测因素.

主要成果:

158名患者符合纳入标准;中位数年龄为74岁,中位数ASA为2,中位数查尔森并发症指数 (CCI) 为5.
在IPSS (-5分),QoL (-1分),PV (-19cc),PVR (-45cc) 和PSA (-1.1 ng/mL) 中观察到显著的改善 (p < 0.01).
Qmax提高了4毫升/秒 (p < 0.01).
临床失败发生在30.3%的患者中,与单边栓塞相关 (p < 0.01).
更高的CCI,更高的PVR和更大的微球预测了更差的结果 (ORs2.17,1.02,26.83;p<0.01).

结论:

在老年,多病性BPH患者中,PAE证明了安全性和有效性.
对CCI和PVR的程序前评估对于优化PAE结果至关重要.
在复杂的BPH病例中,PAE提供了一种可行的治疗选择.

关键词:

良性前列腺增生症良性前列腺增生症年长的老人老年人老年人.国际前列腺症状评分国际前列腺症状评分最少侵入性的外科治疗.前列腺动脉栓塞的前列腺动脉栓塞

更多相关视频

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...